{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-25-000103","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.322168+00:00","generated_at":"2026-05-16T20:14:27.289723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurogene Q3 2025: $21M net loss; NGN-401 gene therapy shows 35 skill acquisitions, registrational trial started","bullets":["Net loss of $21.0M for Q3 2025 vs $20.2M in Q3 2024; R&D expenses $17.2M, G&A $6.6M.","Positive interim Phase 1/2 data: 35 developmental milestones/skills acquired across 8 pediatric participants; durable CGI-I gains.","First participant dosed in Embolden registrational trial for Rett syndrome; enrollment expected in 3-6 months.","Cash, equivalents, investments of $265.4M as of Sep 30, 2025; runway through Q1 2028.","Preclinical data showed ICV delivery superior to IT-L for AAV biodistribution in key brain regions."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-25-000103","json":"https://secwatch.observer/filing/0001404644-25-000103.json","markdown":"https://secwatch.observer/filing/0001404644-25-000103.md","text":"https://secwatch.observer/filing/0001404644-25-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/0001404644-25-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/ngne-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:14:27.289723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}